Actively Recruiting
Phase II Trial of Utidelone Injection Combined with Capecitabine for HER2-negative Breast Cancer Patients with Brain Metastases
Led by Biostar Pharma, Inc. · Updated on 2026-08-21
120
Participants Needed
12
Research Sites
25 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effect of utidelone combined with capecitabine in patients who have HER2-negative breast cancer that has spread to the brain. This Phase II trial aims to assess how well utidelone alone or together with capecitabine works to control tumors inside the brain and elsewhere in the body for these patients. Participants will receive utidelone intravenously once daily for five days every 21 days, either alone or combined with capecitabine taken orally twice daily for up to 14 days in a 21-day cycle. The study includes two stages with different groups receiving either monotherapy or combination treatments to compare outcomes. During the trial, participants will undergo regular brain MRI scans and other assessments to measure tumor response using RECIST 1.1 and RANO-BM criteria over 12 months. Researchers will monitor progression-free survival, overall survival up to 24 months, and treatment-related side effects. The study requires participants to attend visits for evaluations and follow-up testing throughout the treatment and observation periods.
CONDITIONS
Brief Title
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
Research Team
S
Simon Guan
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here